Evidence map›Paper›PMID 34359372›Full record

ArticleDiagnostics (Basel, Switzerland)2021

Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis.

Volodymyr Gavrysyuk, Ievgenia Merenkova, Yaroslav Dziublyk, Nataliia Morska, Nataliia Pendalchuk, Olesia Bychenko, Nataliia Vlasova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. [Sarcoidosis].Zeitschrift fur Rheumatologie · 2023
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Volodymyr GavrysyukDepartment of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine.ORCID 0000-0001-6942-4504
Ievgenia MerenkovaDepartment of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine.ORCID 0000-0003-1299-7058
Yaroslav DziublykDepartment of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine.ORCID 0000-0002-6497-5267
Nataliia MorskaDepartment of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine.ORCID 0000-0001-5255-8290
Nataliia PendalchukDepartment of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine.ORCID 0000-0001-7875-3561
Olesia BychenkoDepartment of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine.
Nataliia VlasovaDepartment of Differential Diagnosis of Tuberculosis and Nonspecific Lung Deseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine.ORCID 0000-0002-7590-4704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate. PURPOSE: The aim of our study was to evaluate primary and long-term outcomes of using MTX and MP in patients with pulmonary sarcoidosis.

methodsA total of 143 patients with newly diagnosed pulmonary sarcoidosis, verified by high-resolution computed tomography (CT) data, were examined. Corticosteroid (CS) therapy was used in 97 patients using MP at a dose of 0.4 mg/kg body weight for 4 weeks, followed by a dose reduction to 0.1 mg/kg by the end of the sixth month. The total duration of CS therapy was 12 months on average. Forty-six patients were treated with MTX at a dose of 10 mg/week (28) and 15 mg/week (18) per os for 6 to 12 months. The study of the relapse rate was conducted within 12 months after the CT data normalization in 60 patients after CS therapy and in 24 after MTX treatment.

resultsMP treatment was successfully completed in 68 (70.1%), and MTX in 29 (60.4%) patients. In five MP patients (5.2%) and in five (10.9%) MTX, treatment was discontinued due to serious side effects. In seven (7.2%) MP patients and ten (21.7%) MTX patients, treatment required additional therapy due to the lack of efficacy. Progression with MP treatment (17-17.5%) was more common than with MTX (2-4.3%; Chi square = 4.703,

conclusionIn patients with pulmonary sarcoidosis, MTX monotherapy does not differ significantly from MP monotherapy in terms of the level of efficacy and the rate of serious side effects. Increasing the MTX dose from 10 to 15 mg/week accelerates the rate of regression of sarcoidosis, improves treatment efficacy, and does not affect the rate of serious side effects. When using MTX, there is a significant decrease in the incidence of treatment resistance and the relapse rate.

Indexed as

methotrexatemethylprednisoloneoutcomespulmonary sarcoidosis

Identifiers

PMID34359372
PMCPMC8304978
OpenAlexW3183517738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.